ClinicalTrials.gg
CompletedNCT00141687Updated Sep 15, 2016

Early External Cephalic Version (ECV) 2 Trial

An interventional study of Early ECV between 34 0/7 and 35 6/7 weeks and Delayed ECV at or after 37 0/7 weeks in Breech Presentation, sponsored by McMaster University. Completed at 1 site in Canada. Open to female participants aged 14 Years to 45 Years. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by McMaster University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,543
Allocation
Randomized
Ages
14 Years to 45 Years
Sex
Female
01

Study summary

For women with a fetus in breech presentation, does early ECV (at 34 0/7 up to 35 weeks and 6/7 days) versus delayed ECV (not before 37 weeks and 0/7 days) increase or decrease the likelihood of cesarean section (CS)?

Read the detailed description

Primary Outcomes: Rate of Caesarean section

Secondary Outcomes: Rate of preterm birth

Other Outcomes: admission to neonatal intensive care unit ≥ 24 hours, perinatal or neonatal mortality or serious neonatal morbidity, serious fetal complications, maternal death or serious maternal morbidity, non-cephalic presentation at birth, women's views, and health care costs.

The Data Coordination for this study is being carried out at the Maternal, Infant Reproductive Health Research Unit at Sunnybrook and Women's College Health Sciences Centre.

02

Conditions studied

  • Breech Presentation

Browse trials for

Keywords

  • External cephalic version
  • Cesarean section
  • pregnancy
  • labour
  • Breech pregnancy
03

In context

Breech Presentation

40 studies on the registry are indexed under Breech Presentation; 10 are open to participants now.

This study's enrollment of 1,543 is above the median of 120 across 29 interventional studies indexed under Breech Presentation.

Browse Breech Presentation studies →

Lead sponsor

McMaster University is the lead sponsor of 738 studies on the registry; 125 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women with any breech presentation
  2. A live singleton fetus
  3. Gestational age of 33 weeks 0 days to 35 weeks 6 days

Exclusion criteria

Exclusion Criteria:

  1. Contraindications to ECV (e.g. fetal heart rate abnormalities, abruptio placenta, major life-threatening fetal anomalies, uterine anomalies, hyper-extended fetal head, rupture of membranes, severe oligohydramnios, severe polyhydramnios)
  2. Contraindications to early ECV (e.g. increased risk of preterm labour [such as past history of preterm labour in this or previous pregnancies], increased risk of abruptio placenta [such as maternal hypertension])
  3. Contraindications to labour or vaginal delivery (e.g. placenta previa, previous classical CS)
  4. Women planning delivery by CS if the fetus turns to cephalic
  5. Women planning a vaginal delivery if the fetus remains breech
  6. Women at increased risk of unstable lie (eg. grand multiparity)
  7. Previous participation in EECV2 Trial
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,543 participants (actual)

Study arms

  • Experimental
    Early External Cephalic Version Group

    Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation

    Procedure: Early ECV between 34 0/7 and 35 6/7 weeks

  • Active comparator
    Delayed External Cephalic Version Group

    Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation

    Procedure: Delayed ECV at or after 37 0/7 weeks

Interventions

  • ProcedureEarly ECV between 34 0/7 and 35 6/7 weeks

    Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation

    Also known as: Early External Cephalic Version (ECV)

  • ProcedureDelayed ECV at or after 37 0/7 weeks

    Delayed external cephalic version at or after 37 0/7 weeks of gestation

    Also known as: Delayed External Cephalic Version (ECV)

06

What researchers measure

Primary outcomes

  1. Rate of cesarean section

    Time frame: Information not available

Secondary outcomes

  1. Rate of pre-term births. Other outcomes: admission to neonatal intensive care unit ≥ 24 hours, perinatal or neonatal mortality or serious neonatal morbidity, or others.

    Time frame: Information not available

07

Study locations

1 site
  • McMaster University
    Hamilton, Ontario L8N 3Z5, Canada
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141687
Collaborators
Canadian Institutes of Health Research (CIHR), University of British Columbia
Responsible party
Eileen Hutton (Professor, Department of Obstetrics & Gynecology, McMaster University) — Principal investigator
First posted
Sep 1, 2005
Start date
Dec 2004
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Sep 15, 2016

Study contacts

Dr. Eileen Hutton, PhD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion